New measurements of human sperm motility as a prediction of fertility
| ISRCTN | ISRCTN11635332 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN11635332 |
| Sponsor | University of Birmingham |
| Funders | Birmingham Women's and Children's NHS Foundation Trust, Investigator initiated and funded |
- Submission date
- 02/10/2026
- Registration date
- 07/10/2026
- Last edited
- 07/10/2026
- Recruitment status
- Recruiting
- Overall study status
- Ongoing
- Condition category
- Urological and Genital Diseases
Plain English summary of protocol
Background and study aims
To fertilize the egg, sperm must accomplish several complicated tasks and only display many of their skills once inside the female genital tract. Activation of motility, swimming at low and high viscosity, navigation, and a particularly intense movement called hyperactivation are all thought to be crucial for natural and at a lesser level, for IVF fertility success.
This means that the detail of how a sperm swims is a key potential diagnostic factor. In this trial the Birmingham team are deploying a novel software system that analyses videos of the sperm observed on the microscope in routine practice for fertility assessment and treatment. The study will then examine whether the detailed AI analysis of the sperm motility can be correlated to the reproductive outcomes for the associated people having treatment. There are no additional interventions in treatment - nothing happens differently to them - but we hope that analysis of the data afterwards will allow us to identify certain critical sperm movement factors that would inform future trials, changing the treatment people received and reducing the chance of inappropriate treatments not working.
The aim is to discover whether newly created software that can measure details of sperm tail beat is a better diagnostic of fertility potential and outcomes than simple sperm counts.
Who can participate?
All individuals undergoing fertility treatments in participating sites that have swimming sperm.
What does the study involve?
There is no change to any treatment or care, video observations of sperm motility in the laboratory prepared sperm will be analysed and compared to the outcomes of treatment.
What are the possible benefits and risks of participating?
No risks or benefits to the participants, but you will be part of a study that may help people in the future.
Where is the study run from?
The study is being led from the Centre for Human Reproductive Science at the University of Birmingham and Birmingham Women’s Hospital (UK).
When is the study starting and how long is it expected to run for?
October 2026 to September 2030.
Who is funding the study?
Birmingham Women's and Children's NHS Foundation Trust (UK).
Who is the main contact?
Professor Jackson Kirkman-Brown, j.kirkmanbrown@bham.ac.uk
Dr Meurig Gallagher, m.t.gallagher@bham.ac.uk
Contact information
Principal investigator
Centre for Human Reproductive Science
College of Medicine & Health
The University of Birmingham
Edgbaston
Birmingham
B15 2TT
United Kingdom
| 0000-0003-2833-8970 | |
| j.kirkmanbrown@bham.ac.uk |
Scientific
Centre for Human Reproductive Science
College of Medicine & Health
The University of Birmingham
Edgbaston
Birmingham
B15 2TT
United Kingdom
| 0000-0002-6512-4472 | |
| m.t.gallagher@bham.ac.uk |
Public
Birmingham Women's Hospital
R&D Gynae Team
Birmingham
B15 2TG
United Kingdom
| Phone | +44 7469 375 162 |
|---|---|
| researchdonor@bham.ac.uk |
Study information
| Primary study design | Observational |
|---|---|
| Observational study design | Case series |
| Scientific title | MotilitY diagnostics in Insemination – The My-I Project |
| Study acronym | My-I |
| Study objectives | My-I is a multi-centre, multi-country evaluation of the potential of sperm flagellar movement as a novel prognostic in ART outcome. The primary objective of the clinical project is to determine whether there is a useful prognostic link between flagellar motility where the primary outcome measure is determination of the impact of the intervention on CPR based on detection of fetal heartbeat and/or fetal sac at 6-9 weeks’ gestation. Secondary objectives will include LBR ≥37 weeks’ gestation, miscarriage rate defined as pregnancy loss after confirmation of clinical pregnancy; and conception or fertilisation rates. |
| Ethics approval(s) | Ethics approval not required |
| Health condition(s) or problem(s) studied | Fertility; infertility; semen analysis; sperm testing |
| Methodology | No randomisation will occur in this project, all participants follow the standard care clinical treatment pathway as comparable patients not in the study, just with anonymised post-hoc analysis as outlined in the trial protocol. The only difference being that My-I will incorporate the analysis of microscopy videos of sperm in existing ART preparations. |
| Intervention type | Other |
| Primary outcome measure(s) |
|
| Key secondary outcome measure(s) | |
| Completion date | 01/09/2030 |
Eligibility
| Participant type(s) | |
|---|---|
| Age group | Mixed |
| Lower age limit | 18 Years |
| Upper age limit | 100 Years |
| Sex | All |
| Target sample size at registration | 6000 |
| Key inclusion criteria | My-I will take data from multiple leading ART assisted conception units across the world. All participating sites will be recognised teaching institutions (or equivalent) accredited in the performance of ART fertility treatments and have been initially selected on the basis of potentially high-quality data provision, with sufficient patient throughput. 1. Couples/individuals able to provide informed consent (where required) 2. Couples/individuals undergoing ART procedure 3. Female: 3.1. Age: 18+ years 4. Male/donor: 4.1. Age: 18+ years 4.2. Motile sperm available for the treatment cycle 4.3. For couples or individuals using donor sperm, consent of the female partner is all that is required (donor consent not required) 4.4. For couples or individuals using donor oocytes, consent of the partner providing the sperm is all that is required (if donor sperm no consent required) |
| Key exclusion criteria | Couples/individuals who have not consented prior to ART procedure will be ineligible (where consent is required) |
| Date of first enrolment | 01/10/2026 |
| Date of final enrolment | 31/12/2029 |
Locations
Countries of recruitment
- United Kingdom
- England
- Australia
- Belgium
- Greece
- South Africa
Study participating centre
Mendelssohn Drive
Edgbaston
Birmingham
B15 2TG
England
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|
Editorial Notes
07/10/2026: Trial's existence confirmed by NHS HRA.